Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) lost 0.5% and 0.9% ...

Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year appears to have investors spooked. Teva on Wednesday reported that ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has opened the reporting season for Israeli companies by publishing its fourth quarter and full-year 2024 financial results. In the ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Promising review: "It is an awesome retro sneaker and I am really happy with the way they look. They are very comfortable, ...

After hours: 7:59:26 p.m. EST ...

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...